

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

**PEPTIDE PRODUCTION WORKSHOP CAPACITY EXPANSION
PROJECT BY THE COMPANY'S SUBSIDIARY, STA
PHARMACEUTICAL**

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) on a voluntary basis.

Currently, Shanghai SynTheAll Pharmaceutical Co., Ltd. (上海合全藥業股份有限公司) (“**STA Pharmaceutical**”), a subsidiary of the Company, is undertaking the peptide production workshop capacity expansion project at its two sites in Changzhou and Taixing (the “**Peptide Production Workshop Capacity Expansion Project**”). The Peptide Production Workshop Capacity Expansion Project will further enhance the capabilities and capacity of the WuXi TIDES platform. As an integral part of STA Pharmaceutical, WuXi TIDES is an end-to-end CRDMO platform that provides one-stop services covering drug discovery, CMC research, and production for oligonucleotides, peptides and related chemically conjugated drugs.

**BASIC INFORMATION ABOUT THE PEPTIDE PRODUCTION
WORKSHOP CAPACITY EXPANSION PROJECT**

STA Pharmaceutical has initiated the peptide capacity expansion at the Changzhou site and the Taixing site. Upon completion, several new peptide solid phase synthesis production lines will be added to STA Pharmaceutical. The expanded workshops are expected to commence operation in December 2023, and the Company's total reactor volume related to peptide solid phase synthesizers will be increased from the originally expected 20,000L to 32,000L by then.

IMPACT ON THE COMPANY

The Peptide Production Workshop Capacity Expansion Project will significantly enhance the Company's peptide production capacity and the capabilities of WuXi TIDES platform, improving its competitiveness in the global market and supporting its long-term growth, while better meeting the growing demand of global partners in peptide drug development and manufacturing, as well as bringing more innovative therapies to patients.

Following the completion of the Peptide Production Workshop Capacity Expansion Project, a certain period of time will still be required for the full production capacity to be realised and released. Subsequent production may also face potential risks in the future, including but not limited to potential market environment changes, industry policy adjustments, intensified competition and end-user demand adjustments. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, September 27, 2023

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purpose only*